Umass Memorial Medical Center
- Type
- Teaching hospital
- Where
- Worcester, MA
- Medicare CCN
- 220163
- Received
- $1,676,406 in 192 records, 2023 ($702,038 general, $974,368 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: UMASS MEMORIAL MEDICAL CENTER, INC. Fuzzy (name and state)
- Nonprofit contractor: UMASS MEMORIAL MEDICAL CENTER INC Fuzzy (name and state)
- Federal award recipient: UMASS MEMORIAL MEDICAL CENTER, INC. Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2023 | General payment | 118 | $702,038 |
| 2023 | Research payment | 74 | $974,368 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| PFIZER INC. | 3 | $727,735 | 2023 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $508,737 | 2023 |
| Olympus America Inc. | 1 | $100,950 | 2023 |
| Route 92 Medical, Inc. | 1 | $87,493 | 2023 |
| KCI USA, Inc. | 1 | $55,388 | 2023 |
| Amylyx Pharmaceuticals, Inc. | 2 | $29,613 | 2023 |
| Insulet Corporation | 20 | $27,000 | 2023 |
| Tandem Diabetes Care, Inc. | 45 | $23,250 | 2023 |
| E.R. Squibb & Sons, L.L.C. | 1 | $18,220 | 2023 |
| M.A. Med Alliance S.A. | 1 | $14,660 | 2023 |
| Stryker Corporation | 11 | $11,879 | 2023 |
| ARGENX US, INC. | 1 | $11,000 | 2023 |
| Incyte Corporation | 9 | $9,690 | 2023 |
| MED-EL Corporation | 1 | $7,950 | 2023 |
| GUERBET LLC | 24 | $6,107 | 2023 |
| Philips North America LLC | 1 | $6,000 | 2023 |
| McKesson Drug Company LLC | 2 | $5,000 | 2023 |
| Celgene Corporation | 3 | $4,420 | 2023 |
| Boston Scientific Corporation | 1 | $4,315 | 2023 |
| Linde Gas & Equipment Inc. | 9 | $2,970 | 2023 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $2,900 | 2023 |
| McKesson Plasma and Biologics LLC | 1 | $2,500 | 2023 |
| Janssen Research & Development, LLC | 1 | $2,302 | 2023 |
| Organon Llc | 3 | $2,100 | 2023 |
| Hubly Incorporated | 1 | $1,200 | 2023 |
| Microline Surgical Inc | 3 | $1,050 | 2023 |
| Abbott Laboratories | 1 | $800 | 2023 |
| KLS-Martin L.P. | 2 | $704 | 2023 |
| Cardiovascular Systems Inc. | 1 | $468 | 2023 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 74 | $974,368 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 83 | $507,230 |
| Debt forgiveness | 3 | $101,654 |
| Royalty or License | 1 | $55,388 |
| Long term medical supply or device loan | 19 | $27,295 |
| Charitable Contribution | 3 | $7,500 |
| Space rental or facility fees (teaching hospital only) | 9 | $2,970 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | Philips North America LLC | $6,000 | Research payment | In-kind items and services | (6260) Ingenia 3 0T R5 Device, Medical Device | Next Generation Quantitative Subcortical Imaging | 2023 |
| 2023-12-31 | Stryker Corporation | $5,102 | Long term medical supply or device loan | In-kind items and services | EZOUT Device, SURGICAL | 2023 | |
| 2023-12-31 | Stryker Corporation | $4,019 | Long term medical supply or device loan | In-kind items and services | EZOUT Device, SURGICAL | 2023 | |
| 2023-12-31 | Stryker Corporation | $899 | Long term medical supply or device loan | In-kind items and services | PROFORM Device, PATIENT CARE - PC | 2023 | |
| 2023-12-31 | Stryker Corporation | $449 | Long term medical supply or device loan | In-kind items and services | SYMMETRY II SLEEPER CHAIR Device, PATIENT CARE - PC | 2023 | |
| 2023-12-31 | Stryker Corporation | $449 | Long term medical supply or device loan | In-kind items and services | SYMMETRY II SLEEPER CHAIR Device, PATIENT CARE - PC | 2023 | |
| 2023-12-31 | Stryker Corporation | $430 | Long term medical supply or device loan | In-kind items and services | SYMMETRY II SLEEPER CHAIR Device, PATIENT CARE - PC | 2023 | |
| 2023-12-31 | Stryker Corporation | $133 | Long term medical supply or device loan | In-kind items and services | BEDSIDE STAND Device, FURNITURE | 2023 | |
| 2023-12-31 | Stryker Corporation | $98 | Long term medical supply or device loan | In-kind items and services | OVERBED TABLE TRU-FIT Device, FURNITURE | 2023 | |
| 2023-12-31 | Stryker Corporation | $98 | Long term medical supply or device loan | In-kind items and services | OVERBED TABLE TRU-FIT Device, FURNITURE | 2023 | |
| 2023-12-31 | Stryker Corporation | $98 | Long term medical supply or device loan | In-kind items and services | OVERBED TABLE TRU-FIT Device, FURNITURE | 2023 | |
| 2023-12-31 | Stryker Corporation | $98 | Long term medical supply or device loan | In-kind items and services | OVERBED TABLE TRU-FIT Device, FURNITURE | 2023 | |
| 2023-12-21 | E.R. Squibb & Sons, L.L.C. | $18,220 | Research payment | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | A Phase 4, Global, Prospective, Open label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Bioma | 2023 |
| 2023-12-21 | Insulet Corporation | $4,375 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2023 | |
| 2023-12-15 | Microline Surgical Inc | $747 | Long term medical supply or device loan | In-kind items and services | Endoscopic Retractor - Trocar Device, Endoscopic Retractor - Trocar | 2023 | |
| 2023-12-15 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-12-15 | Microline Surgical Inc | $152 | Long term medical supply or device loan | In-kind items and services | Endoscopic Retractor - Percutaneous Device, Endoscopic Retractor - Percutaneous | 2023 | |
| 2023-12-15 | Microline Surgical Inc | $149 | Long term medical supply or device loan | In-kind items and services | Endoscopic Retractor - Trocar Device, Endoscopic Retractor - Trocar | 2023 | |
| 2023-12-13 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-12-08 | McKesson Drug Company LLC | $2,500 | Charitable Contribution | Cash or cash equivalent | 2023 | ||
| 2023-11-30 | Insulet Corporation | $3,775 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2023 | |
| 2023-11-29 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-11-17 | Janssen Research & Development, LLC | $2,302 | Research payment | Cash or cash equivalent | REMICADE Biological, Immunology | DEVELOP | 2023 |
| 2023-11-15 | Takeda Pharmaceuticals U.S.A., Inc. | $1,105 | Research payment | Cash or cash equivalent | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | 2023 | |
| 2023-11-15 | Takeda Pharmaceuticals U.S.A., Inc. | $1,105 | Research payment | Cash or cash equivalent | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | 2023 | |
| 2023-11-15 | Takeda Pharmaceuticals U.S.A., Inc. | $1,105 | Research payment | Cash or cash equivalent | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | 2023 | |
| 2023-11-15 | Takeda Pharmaceuticals U.S.A., Inc. | $591 | Research payment | Cash or cash equivalent | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | 2023 | |
| 2023-11-15 | Takeda Pharmaceuticals U.S.A., Inc. | $591 | Research payment | Cash or cash equivalent | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | 2023 | |
| 2023-11-15 | Takeda Pharmaceuticals U.S.A., Inc. | $591 | Research payment | Cash or cash equivalent | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | 2023 | |
| 2023-11-15 | Takeda Pharmaceuticals U.S.A., Inc. | $390 | Research payment | Cash or cash equivalent | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | 2023 | |
| 2023-11-15 | Takeda Pharmaceuticals U.S.A., Inc. | $390 | Research payment | Cash or cash equivalent | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | 2023 | |
| 2023-11-15 | Takeda Pharmaceuticals U.S.A., Inc. | $390 | Research payment | Cash or cash equivalent | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | 2023 | |
| 2023-11-15 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-11-15 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-11-08 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-11-01 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-10-31 | M.A. Med Alliance S.A. | $14,660 | Research payment | Cash or cash equivalent | SELUTION SLR DEB 014 Device, CARDIOVASCULAR | A Prospective Randomized Multicenter Single Blinded Study to Assess the Safety and Effectiveness of the SELUTION SLR 014 | 2023 |
| 2023-10-26 | Insulet Corporation | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2023 | |
| 2023-10-18 | Insulet Corporation | $1,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2023 | |
| 2023-10-18 | Tandem Diabetes Care, Inc. | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-10-13 | Incyte Corporation | $1,072 | Research payment | Cash or cash equivalent | A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy | 2023 | |
| 2023-10-11 | Incyte Corporation | $1,072 | Research payment | Cash or cash equivalent | A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy | 2023 | |
| 2023-10-11 | Tandem Diabetes Care, Inc. | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-10-05 | Insulet Corporation | $1,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2023 | |
| 2023-10-04 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-10-02 | Takeda Pharmaceuticals U.S.A., Inc. | $4,200 | Research payment | Cash or cash equivalent | A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF | 2023 | |
| 2023-10-02 | Takeda Pharmaceuticals U.S.A., Inc. | $780 | Research payment | Cash or cash equivalent | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | 2023 | |
| 2023-10-02 | Takeda Pharmaceuticals U.S.A., Inc. | $715 | Research payment | Cash or cash equivalent | A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF | 2023 | |
| 2023-09-27 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-09-20 | Tandem Diabetes Care, Inc. | $850 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-09-13 | Tandem Diabetes Care, Inc. | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-09-12 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-09-06 | Tandem Diabetes Care, Inc. | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-09-06 | GUERBET LLC | $8 | Research payment | Cash or cash equivalent | Dotarem Drug, Gadolinium-based Contrast Agent | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonanc | 2023 |
| 2023-09-06 | GUERBET LLC | $8 | Research payment | Cash or cash equivalent | Dotarem Drug, Gadolinium-based Contrast Agent | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonanc | 2023 |
| 2023-09-05 | Insulet Corporation | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2023 | |
| 2023-09-05 | Insulet Corporation | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2023 | |
| 2023-08-30 | Tandem Diabetes Care, Inc. | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-08-25 | Insulet Corporation | $900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2023 | |
| 2023-08-23 | Celgene Corporation | $1,300 | Research payment | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | PhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202) | 2023 |
| 2023-08-23 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-08-23 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-08-22 | Incyte Corporation | $472 | Research payment | Cash or cash equivalent | A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy | 2023 | |
| 2023-08-18 | Celgene Corporation | $1,300 | Research payment | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | Ph III Yellowstone CD Maintenance (RPC01-3203) - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled St | 2023 |
| 2023-08-16 | Tandem Diabetes Care, Inc. | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-08-16 | PFIZER INC. | $240 | Research payment | In-kind items and services | PAXLOVID Drug, INFECTIOUS DISEASES | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL | 2023 |
| 2023-08-11 | Organon Llc | $700 | Long term medical supply or device loan | In-kind items and services | JADA SYSTEM Device, POSTPARTUM UTERINE HEMORRHAGING | 2023 | |
| 2023-08-10 | Insulet Corporation | $1,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2023 | |
| 2023-08-10 | Organon Llc | $700 | Long term medical supply or device loan | In-kind items and services | JADA SYSTEM Device, POSTPARTUM UTERINE HEMORRHAGING | 2023 | |
| 2023-08-09 | Tandem Diabetes Care, Inc. | $850 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-08-09 | Organon Llc | $700 | Long term medical supply or device loan | In-kind items and services | JADA SYSTEM Device, POSTPARTUM UTERINE HEMORRHAGING | 2023 | |
| 2023-08-03 | Incyte Corporation | $1,458 | Research payment | Cash or cash equivalent | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBRO | 2023 | |
| 2023-08-01 | Celgene Corporation | $1,820 | Research payment | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | Ph III Yellowstone CD OLE (RPC01-3204) - A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderat | 2023 |
| 2023-07-26 | Tandem Diabetes Care, Inc. | $1,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-07-26 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-07-24 | GUERBET LLC | $1,019 | Research payment | Cash or cash equivalent | Dotarem Drug, Gadolinium-based Contrast Agent | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonanc | 2023 |
| 2023-07-24 | GUERBET LLC | $341 | Research payment | Cash or cash equivalent | Dotarem Drug, Gadolinium-based Contrast Agent | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonanc | 2023 |
| 2023-07-20 | Insulet Corporation | $1,450 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2023 | |
| 2023-07-19 | Takeda Pharmaceuticals U.S.A., Inc. | $789 | Research payment | Cash or cash equivalent | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | 2023 | |
| 2023-07-19 | Takeda Pharmaceuticals U.S.A., Inc. | $789 | Research payment | Cash or cash equivalent | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | 2023 | |
| 2023-07-19 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-07-14 | GUERBET LLC | $162 | Research payment | Cash or cash equivalent | Dotarem Drug, Gadolinium-based Contrast Agent | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonanc | 2023 |
| 2023-07-14 | GUERBET LLC | $14 | Research payment | Cash or cash equivalent | Dotarem Drug, Gadolinium-based Contrast Agent | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonanc | 2023 |
| 2023-07-14 | GUERBET LLC | $14 | Research payment | Cash or cash equivalent | Dotarem Drug, Gadolinium-based Contrast Agent | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonanc | 2023 |
| 2023-07-14 | GUERBET LLC | $14 | Research payment | Cash or cash equivalent | Dotarem Drug, Gadolinium-based Contrast Agent | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonanc | 2023 |
| 2023-07-14 | GUERBET LLC | $14 | Research payment | Cash or cash equivalent | Dotarem Drug, Gadolinium-based Contrast Agent | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonanc | 2023 |
| 2023-07-14 | GUERBET LLC | $10 | Research payment | Cash or cash equivalent | Dotarem Drug, Gadolinium-based Contrast Agent | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonanc | 2023 |
| 2023-07-14 | GUERBET LLC | $4 | Research payment | Cash or cash equivalent | Dotarem Drug, Gadolinium-based Contrast Agent | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonanc | 2023 |
| 2023-07-14 | GUERBET LLC | $4 | Research payment | Cash or cash equivalent | Dotarem Drug, Gadolinium-based Contrast Agent | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonanc | 2023 |
| 2023-07-12 | Takeda Pharmaceuticals U.S.A., Inc. | $54,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-07-12 | Takeda Pharmaceuticals U.S.A., Inc. | $6,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-07-07 | Takeda Pharmaceuticals U.S.A., Inc. | $390 | Research payment | Cash or cash equivalent | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | 2023 | |
| 2023-07-07 | Takeda Pharmaceuticals U.S.A., Inc. | $390 | Research payment | Cash or cash equivalent | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | 2023 | |
| 2023-07-07 | Takeda Pharmaceuticals U.S.A., Inc. | $354 | Research payment | Cash or cash equivalent | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | 2023 | |
| 2023-07-07 | Takeda Pharmaceuticals U.S.A., Inc. | $354 | Research payment | Cash or cash equivalent | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | 2023 | |
| 2023-07-05 | GUERBET LLC | $2 | Research payment | Cash or cash equivalent | Dotarem Drug, Gadolinium-based Contrast Agent | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonanc | 2023 |
| 2023-06-30 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-06-28 | ARGENX US, INC. | $11,000 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Immunology | Vials volume Analysis Project | 2023 |
| 2023-06-28 | Tandem Diabetes Care, Inc. | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-06-28 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-06-27 | Insulet Corporation | $1,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2023 | |
| 2023-06-27 | Abbott Laboratories | $800 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Vascular | Evaluation of Treatment Strategies for Severe Calcific Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplas | 2023 |
| 2023-06-23 | MED-EL Corporation | $7,950 | Long term medical supply or device loan | In-kind items and services | Mi1250 SYNCHRONY 2 FLEXsoft Device, Cochlear Implant | 2023 | |
| 2023-06-22 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-06-22 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-06-16 | Takeda Pharmaceuticals U.S.A., Inc. | $6,130 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-15 | Tandem Diabetes Care, Inc. | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-06-14 | Takeda Pharmaceuticals U.S.A., Inc. | $18,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-14 | Takeda Pharmaceuticals U.S.A., Inc. | $12,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-14 | Takeda Pharmaceuticals U.S.A., Inc. | $6,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-14 | Takeda Pharmaceuticals U.S.A., Inc. | $6,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-13 | PFIZER INC. | $2,495 | Research payment | In-kind items and services | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2023 | |
| 2023-06-08 | Insulet Corporation | $650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2023 | |
| 2023-06-07 | Tandem Diabetes Care, Inc. | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-06-06 | GUERBET LLC | $4 | Research payment | Cash or cash equivalent | Dotarem Drug, Gadolinium-based Contrast Agent | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonanc | 2023 |
| 2023-06-05 | Takeda Pharmaceuticals U.S.A., Inc. | $15,000 | Research payment | Cash or cash equivalent | Validation of K16ApoE peptide formulations for viral delivery to the CNS | 2023 | |
| 2023-06-02 | Takeda Pharmaceuticals U.S.A., Inc. | $25,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-02 | Takeda Pharmaceuticals U.S.A., Inc. | $25,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-02 | Takeda Pharmaceuticals U.S.A., Inc. | $18,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-02 | Takeda Pharmaceuticals U.S.A., Inc. | $12,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-02 | Takeda Pharmaceuticals U.S.A., Inc. | $6,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-01 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-05-31 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-05-23 | GUERBET LLC | $1,019 | Research payment | Cash or cash equivalent | Dotarem Drug, Gadolinium-based Contrast Agent | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonanc | 2023 |
| 2023-05-23 | GUERBET LLC | $341 | Research payment | Cash or cash equivalent | Dotarem Drug, Gadolinium-based Contrast Agent | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonanc | 2023 |
| 2023-05-18 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-05-17 | Insulet Corporation | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2023 | |
| 2023-05-10 | Amylyx Pharmaceuticals, Inc. | $7,451 | Research payment | Cash or cash equivalent | RELYVRIO Drug, NEUROLOGY | Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment (Phoenix) | 2023 |
| 2023-05-10 | Takeda Pharmaceuticals U.S.A., Inc. | $5,088 | Research payment | Cash or cash equivalent | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | 2023 | |
| 2023-05-10 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-05-05 | Takeda Pharmaceuticals U.S.A., Inc. | $2,708 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 2 DOSE | 2023 | |
| 2023-05-05 | Incyte Corporation | $473 | Research payment | Cash or cash equivalent | A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy | 2023 | |
| 2023-05-04 | Route 92 Medical, Inc. | $87,493 | Research payment | Cash or cash equivalent | HIPOINT 088 Device, NEURO ASPIRATION | SUMMIT MAX | 2023 |
| 2023-05-03 | Insulet Corporation | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2023 | |
| 2023-04-26 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-04-19 | GUERBET LLC | $1,987 | Research payment | Cash or cash equivalent | Dotarem Drug, Gadolinium-based Contrast Agent | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonanc | 2023 |
| 2023-04-19 | Tandem Diabetes Care, Inc. | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-04-19 | GUERBET LLC | $405 | Research payment | Cash or cash equivalent | Dotarem Drug, Gadolinium-based Contrast Agent | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonanc | 2023 |
| 2023-04-19 | GUERBET LLC | $351 | Research payment | Cash or cash equivalent | Dotarem Drug, Gadolinium-based Contrast Agent | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonanc | 2023 |
| 2023-04-19 | GUERBET LLC | $270 | Research payment | Cash or cash equivalent | Dotarem Drug, Gadolinium-based Contrast Agent | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonanc | 2023 |
| 2023-04-18 | Hubly Incorporated | $1,200 | Research payment | Cash or cash equivalent | Hubly Electric Drill Device, Drills, Burrs, Trephines & Accessories (Simple, Powered) | 2023 | |
| 2023-04-12 | Takeda Pharmaceuticals U.S.A., Inc. | $18,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-04-12 | Takeda Pharmaceuticals U.S.A., Inc. | $6,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-04-12 | Tandem Diabetes Care, Inc. | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-04-10 | Incyte Corporation | $32 | Research payment | Cash or cash equivalent | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBRO | 2023 | |
| 2023-04-10 | Incyte Corporation | $0 | Research payment | Cash or cash equivalent | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBRO | 2023 | |
| 2023-04-07 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-04-05 | Takeda Pharmaceuticals U.S.A., Inc. | $151,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-04-05 | Takeda Pharmaceuticals U.S.A., Inc. | $61,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-04-05 | Tandem Diabetes Care, Inc. | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-03-31 | KLS-Martin L.P. | $417 | Debt forgiveness | Cash or cash equivalent | OSTEOTOME,BURTON, 11 MM TIP,23 CM,QTY:001 EA Device, Instrument | 2023 | |
| 2023-03-31 | KLS-Martin L.P. | $287 | Debt forgiveness | Cash or cash equivalent | OSTEOTOME,PTERYGOID, HARGIS, 9.7 MM TIP,22 CM,QTY:001 EA Device, Instrument | 2023 | |
| 2023-03-29 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-03-24 | McKesson Drug Company LLC | $2,500 | Charitable Contribution | Cash or cash equivalent | 2023 | ||
| 2023-03-23 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-03-22 | Tandem Diabetes Care, Inc. | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-03-21 | McKesson Plasma and Biologics LLC | $2,500 | Charitable Contribution | Cash or cash equivalent | 2023 | ||
| 2023-03-20 | Insulet Corporation | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2023 | |
| 2023-03-16 | Amylyx Pharmaceuticals, Inc. | $22,162 | Research payment | Cash or cash equivalent | RELYVRIO Drug, NEUROLOGY | Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment (Phoenix) | 2023 |
| 2023-03-15 | Tandem Diabetes Care, Inc. | $850 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-03-14 | GUERBET LLC | $81 | Research payment | Cash or cash equivalent | Dotarem Drug, Gadolinium-based Contrast Agent | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonanc | 2023 |
| 2023-03-09 | Incyte Corporation | $3,606 | Research payment | Cash or cash equivalent | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBRO | 2023 | |
| 2023-03-09 | Insulet Corporation | $200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2023 | |
| 2023-03-08 | Takeda Pharmaceuticals U.S.A., Inc. | $12,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-03-08 | Takeda Pharmaceuticals U.S.A., Inc. | $6,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-03-08 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-03-03 | Olympus America Inc. | $100,950 | Debt forgiveness | In-kind items and services | EVIS EXERA III VIDEO SYSTEM CENTER Device, Gastroenterology | 2023 | |
| 2023-03-01 | KCI USA, Inc. | $55,388 | Royalty or License | Cash or cash equivalent | ABTHERA ADVANCE Device, Negative Pressure Systems & Dressings | 2023 | |
| 2023-03-01 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-02-27 | PFIZER INC. | $725,000 | Research payment | Cash or cash equivalent | NEXT GENERATION RAAV MANUFACTURING PROJECT 1 CELLULAR FACTORS PROJECT 2 AAV REP | 2023 | |
| 2023-02-23 | Tandem Diabetes Care, Inc. | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-02-15 | Insulet Corporation | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2023 | |
| 2023-02-15 | Tandem Diabetes Care, Inc. | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-02-09 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2023 | |
| 2023-02-09 | Insulet Corporation | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2023 | |
| 2023-02-08 | Tandem Diabetes Care, Inc. | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-02-01 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-01-30 | Takeda Pharmaceuticals U.S.A., Inc. | $12,642 | Research payment | Cash or cash equivalent | A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF | 2023 | |
| 2023-01-30 | C. R. Bard, Inc. & Subsidiaries | $2,900 | Research payment | Cash or cash equivalent | Intrepid | 2023 | |
| 2023-01-25 | Tandem Diabetes Care, Inc. | $1,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-01-20 | Insulet Corporation | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2023 | |
| 2023-01-18 | Tandem Diabetes Care, Inc. | $1,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-01-17 | Boston Scientific Corporation | $4,315 | Long term medical supply or device loan | In-kind items and services | AVVIGO Guidance System Device, AVVIGO_IC | 2023 | |
| 2023-01-13 | Cardiovascular Systems Inc. | $468 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2023 |
| 2023-01-11 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-01-06 | GUERBET LLC | $10 | Research payment | Cash or cash equivalent | Dotarem Drug, Gadolinium-based Contrast Agent | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonanc | 2023 |
| 2023-01-06 | GUERBET LLC | $10 | Research payment | Cash or cash equivalent | Dotarem Drug, Gadolinium-based Contrast Agent | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonanc | 2023 |
| 2023-01-06 | GUERBET LLC | $4 | Research payment | Cash or cash equivalent | Dotarem Drug, Gadolinium-based Contrast Agent | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonanc | 2023 |
| 2023-01-05 | Tandem Diabetes Care, Inc. | $1,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2023 | |
| 2023-01-05 | Takeda Pharmaceuticals U.S.A., Inc. | $1,300 | Research payment | Cash or cash equivalent | A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF | 2023 | |
| 2023-01-05 | Insulet Corporation | $900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2023 | |
| 2023-01-04 | Incyte Corporation | $1,500 | Research payment | Cash or cash equivalent | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBRO | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Worcester, MA, county Worcester County, MA, state Massachusetts; placed by its city name.
| Measure | Place (city or town) Worcester, MA | County Worcester County, MA | State Massachusetts |
|---|---|---|---|
| Population B01003 | 207,055 | 867,788 | 7,044,056 |
| Population, 2020 census P1 | 206,518 | 862,111 | 7,029,917 |
| Median age B01002 | 33.9 | 40.2 | 40.0 |
| Under 18 B01001 | 19.6% | 20.6% | 19.4% |
| 65 and over B01001 | 13.3% | 17.0% | 17.9% |
| Households B11001 | 79,501 | 335,826 | 2,785,042 |
| Foreign born B05002 | 25.1% | 14.5% | 18.0% |
| Median household income B19013 | $70,102 | $95,939 | $103,960 |
| Median family income B19113 | $84,516 | $119,408 | $131,675 |
| Per capita income B19301 | $37,221 | $48,914 | $57,897 |
| Poverty rate B17001 | 19.6% | 10.3% | 10.0% |
| Unemployment rate B23025 | 6.5% | 5.3% | 5.2% |
| Civilian labor force B23025 | 111,269 | 471,761 | 3,911,446 |
| Mean commute (minutes) B08013 | 24.1 | 29.2 | 29.1 |
| Bachelor's degree or higher B15003 | 35.2% | 39.7% | 47.3% |
| Housing units B25001 | 85,876 | 355,185 | 3,030,406 |
| Owner-occupied B25003 | 42.8% | 65.8% | 62.5% |
| Renters B25003 | 57.2% | 34.2% | 37.5% |
| Median home value B25077 | $374,400 | $423,700 | $562,100 |
| Median gross rent B25064 | $1,487 | $1,426 | $1,762 |
| White, not Hispanic B03002 | 48.6% | 70.3% | 66.6% |
| Black B03002 | 12.1% | 4.8% | 6.4% |
| Hispanic or Latino B03002 | 25.3% | 13.7% | 13.3% |
| Asian B03002 | 7.2% | 5.3% | 7.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Worcester, MA.
Comments